Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Paritaprevir (ABT450) is an inhibitor of non-structural protein 3/4A protease with EC50 values of 1 and 0.21 nM for HCV 1a and HCV 1b, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 60.00 | |
2 mg | In stock | $ 88.00 | |
5 mg | In stock | $ 147.00 | |
10 mg | In stock | $ 187.00 | |
25 mg | In stock | $ 336.00 | |
50 mg | In stock | $ 547.00 | |
100 mg | In stock | $ 789.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 157.00 |
Description | Paritaprevir (ABT450) is an inhibitor of non-structural protein 3/4A protease with EC50 values of 1 and 0.21 nM for HCV 1a and HCV 1b, respectively. |
Targets&IC50 | HCV 1b:0.21 nM(EC50), HCV NS3/4A 3a:19 nM, HCV NS3/4A 1b:0.21 nM, HCV 1a:1 nM(EC50), HCV NS3/4A 2a:5.3 nM, HCV NS3/4A 1a:1.0 nM, HCV NS3/4A 6a:0.69nM, HCV NS3/4A 4a:0.09 nM |
In vivo | Paritaprevir/ritonavir/ombitasvir with dasabuvir (PrOD) is a novel combination of a nonstructural (NS) 3/4A protein inhibitor boosted by ritonavir, an NS5A protein inhibitor, and an NS5B nonnucleoside polymerase inhibitor. The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections1[1]. |
Synonyms | ABT450, ABT-450, Veruprevir |
Molecular Weight | 765.88 |
Formula | C40H43N7O7S |
CAS No. | 1216941-48-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (104.46 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Paritaprevir 1216941-48-8 Microbiology/Virology Proteases/Proteasome HCV Protease orally active Ritonavir SARS-CoV Hepatitis C virus HCV SARS coronavirus ABT450 ABT-450 ABT 450 NS3/4A Inhibitor CYP450 SARS-CoV 3CLPpro inhibit Veruprevir inhibitor